Vorsetuzumab

• CAT Number: I042434
• CAS Number: 1165740-62-4
• Molecular Weight: 146.1 (kDa)
• Purity: ≥95%

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].
Vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro[1].
Vorsetuzumab (10 μg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1].
Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1].

Reference

[1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.
 [Content Brief]